Top

Published in:

01-08-2013

Exercise Capacity Affects Quality of Life in Patients with Pulmonary Hypertension

Authors: Michael Halank, Franziska Einsle, Stephanie Lehman, Hinrich Bremer, Ralf Ewert, Heinrike Wilkens, F. Joachim Meyer, Ekkehard Grünig, Hans-Jürgen Seyfarth, Martin Kolditz, Gesine Wieder, Gert Höffken, Volker Köllner

Published in: Lung | Issue 4/2013

Abstract

Background

The objective of this prospective study was to evaluate the impact of exercise capacity, mental disorders, and hemodynamics on quality-of-life (QoL) parameters in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

Methods

Sixty-three patients with invasively diagnosed PAH (n = 48) or CTEPH (n = 15) underwent a broad panel of assessments, including cardiopulmonary exercise testing (CPET), 6-minute walking distance (6-MWD), World Health Organization functional class (WHO-FC), and assessment of hemodynamics. QoL was evaluated by the 36-item Medical Outcome Study Short Form Health Survey Questionnaire (SF-36). Exercise capacity, hemodynamics, age, gender, and mental disorders (anxiety and depression) were assessed for association with QoL subscores by uni- and multivariate regression analyses.

Results

Exercise capacity, WHO-FC, oxygen therapy, symptoms of right heart failure, right atrial pressure, and mental disorders were significantly associated with QoL (p < 0.05). In the stepwise backward selection multivariate analysis, depression remained an independent parameter in seven of eight subscales of the SF-36. Furthermore, peak oxygen uptake (peakVO₂) during CPET, 6-MWD, anxiety, long-term oxygen therapy, right heart failure, and age remained independent factors for QoL. Hemodynamic parameters at rest did not independently correlate with any domain of the SF-36 QoL subscores.

Conclusions

Mental disorders, exercise capacity, long-term oxygen therapy, right heart failure, and age play important role in the quality of life in patients with PAH and CTEPH.

Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(1):S43–S54. doi:10.1016/j.jacc.2009.04.012 PubMedCrossRef

Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34(6):1219–1263. doi:10.1183/09031936.00139009 PubMedCrossRef

Condliffe R, Kiely DG, Gibbs JSR, Corris PA, Peacock AJ, Jenkins DP et al (2009) Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J 33(2):332–337. doi:10.1183/09031936.00092008 PubMedCrossRef

Saouti N, de Man F, Westerhof N, Boonstra A, Twisk J, Postmus PE et al (2009) Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respir Med 103(7):1013–1019. doi:10.1016/j.rmed.2009.01.017 PubMedCrossRef

Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX et al (2002) Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106(3):319–324. doi:10.1161/01.CIR.0000022687.08568.2A PubMedCrossRef

Cenedese E, Speich R, Dorschner L, Ulrich S et al (2006) Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 28:808–815. doi:10.1183/09037936.06.00130405 PubMedCrossRef

Grünig E, Lichtblau M, Ehlken N, Ghofrani HA et al (2012) Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J 40:84–92. doi:10.1183/09031936.00123711 PubMedCrossRef

Grünig E, Ehlken N, Ghofrani A, Staehler G et al (2011) Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration 81:394–401. doi:10.1159/000322475 PubMedCrossRef

Strange G, Keogh AM, Williams TJ, Wlodaeczyk J, McNeil K, Gabby E (2008) Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology 13:674–682. doi:10.1111/j.1440-1843.2008.01326.x PubMedCrossRef

10.

Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M (2009) Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 25:2479–2485. doi:10.1185/03007990903210066 PubMedCrossRef

11.

Simonneau G, Rubin LJ, Galie N, Barst RJ et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med 149:521–530PubMedCrossRef

12.

Chua R, Keogh AM, Byth K, O’Loughlin A (2006) Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J 36(11):705–710. doi:10.1111/j.1445-5994.2006.01169.x PubMedCrossRef

13.

Zlupko M, Harhay MO, Gallop R, Shin J, Archer-Chicko C, Patel R et al (2008) Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 102(10):1431–1438. doi:10.1016/j.rmed.2008.04.016 PubMedCrossRef

14.

Löwe B, Gräfe K, Ufer C, Kroenke K, Grünig E, Herzog W et al (2004) Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 66(6):831–836. doi:10.1097/01.psy.0000145593.37594.39 PubMedCrossRef

15.

McCollister DH, Beutz M, McLaughlin V, Rumsfeld J, Masoudi FA, Tripputi M et al (2010) Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics 51(4):339–347PubMed

16.

McHorney CA, Ware JE, Lu JFR, Sherbourne CD (1994) The MOS 36-item short-form Health Survey (SF-36): tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32(1):40–66. doi:10.1097/00005650-199401000-00004 PubMedCrossRef

17.

Bullinger M (1995) German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA project. Soc Sci Med 41(10):1359–1366. doi:10.1016/0277-9536(95)00115-N PubMedCrossRef

18.

American Thoracic Society (2002) ATS Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117. doi:10.1164/rccm.166/1/111 CrossRef

19.

Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S (2002) Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 20(5):1314–1331. doi:10.1183/09031936.02.00068002 PubMedCrossRef

20.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370. doi:10.1111/j.1600-0447.1983.tb09716.x PubMedCrossRef

21.

Herrmann C, Buss U, Snaith R (1995) Hospital anxiety and depression scale (HADS-D) (German version). Huber, Bern

22.

Hinz A, Schwarz R (2001) Angst und Depression in der Allgemeinbevölkerung. Psychother Psychosom Med Psychol 51:193–200PubMedCrossRef

23.

Wensel R, Francis DP, Meyer FJ, Opitz CF et al (in press) Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol. doi:10.1016/j.ijcard.2012.03.135

24.

Looper KJ, Pierre A, Dunkley DM, Sigal JJ, Langleben D (2009) Depressive symptoms in relation to physical functioning in pulmonary hypertension. J Psychosom Res 66(3):221–225. doi:10.1016/j.jpsychores.2008.09.014 PubMedCrossRef

25.

Wittchen HU, Einsle F (2012) Depression, anxiety and somatic complaints - is it all psychosomatic? Medicographia 34(3):307–314

26.

Wilkens H, Grimminger F, Hoeper M, Staehler G, Ehlken B, Plesnila-Frank C et al (2010) Burden of pulmonary arterial hypertension in Germany. Respir Med 104(6):902–910. doi:10.1016/j.rmed.2010.01.002 PubMedCrossRef

27.

Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK (2004) Health-related quality of life in patients with pulmonary arterial hypertension. Chest 126(5):1452–1459. doi:10.1378/chest.126.5.1452 PubMedCrossRef

28.

White J, Hopkins RO, Glissmeyer EW, Kitterman N, Elliott CG (2006) Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension. Respir Res 7(55):1–10. doi:10.1186/1465-9921-7-55

29.

Parry GD, Cooper CL, Moore JM, Yadegarfar G, Campbell MJ, Esmonde L et al (2012) Cognitive behavioural intervention for adults with anxiety complications of asthma: prospective randomised trial. Respir Med 106(6):802–810. doi:10.1016/j.rmed.2012.02.006 PubMedCrossRef

30.

Cuijpers P, Muñoz RF, Clarke GN, Lewinsohn PM (2009) Psychoeducational treatment and prevention of depression: the “coping with depression” course thirty years later. Clin Psychol Rev 29(5):449–458. doi:10.1016/j.cpr.2009.04.005 PubMedCrossRef

31.

Jonkers CCM, Lamers F, Bosma H, Metsemakers JFM, van Eijk JTM (2012) The effectiveness of a minimal psychological intervention on self-management beliefs and behaviors in depressed chronically ill elderly persons: a randomized trial. Int Psychogeriatr 24(2):288–297. doi:10.1017/S1041610211001748 PubMedCrossRef

32.

Rubenfire M, Lippo G, Bodini BD, Blasi F, Allegra L, Bossone E (2009) Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. Chest 136(2):597–603. doi:10.1378/chest.08-1260 PubMedCrossRef

33.

Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E (2011) Validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) for the Australian and New Zealand population. Respirology 16:1235–1240. doi:10.1111/j.1440-1843.2011.02030.x PubMedCrossRef

34.

Cima K, Twiss J, Speich R, McKenna SP, Grünig E, Kähler CM, Ehlken N, Treder U, Crawford SR, Huber LC, Ulrich S (2012) The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR). Health Qual Life 10:110. doi:10.1186/1477-7525-10-110 CrossRef

Title: Exercise Capacity Affects Quality of Life in Patients with Pulmonary Hypertension
Authors: Michael Halank
Franziska Einsle
Stephanie Lehman
Hinrich Bremer
Ralf Ewert
Heinrike Wilkens
F. Joachim Meyer
Ekkehard Grünig
Hans-Jürgen Seyfarth
Martin Kolditz
Gesine Wieder
Gert Höffken
Volker Köllner
Publication date: 01-08-2013
Publisher: Springer US
Published in: Lung / Issue 4/2013
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-013-9472-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Exercise Capacity Affects Quality of Life in Patients with Pulmonary Hypertension

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

The Suppression Effects of Thalidomide on Human Lung Fibroblasts: Cell Proliferation, Vascular Endothelial Growth Factor Release, and Collagen Production

Intima-Media Thickness in Patients With Obstructive Sleep Apnea Without Comorbidities

The Impact of Neoadjuvant Chemotherapy on the Histopathological Assessment of Thymomas: A Clinicopathological Correlation of 28 Cases Treated with a Similar Regimen

Angiotensin-Converting Enzyme (ACE) Gene Polymorphisms are Associated with Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease in a Child with Antisynthetase Syndrome

The Association Between TP53 Arg72Pro Polymorphism and Lung Cancer Susceptibility: Evidence from 30,038 Subjects

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page